Dana-Farber’s Breast Oncology Center shared a post on X:
“Here’s the Breast Cancer Research Digest – a summary of last week’s publications from select high-impact journals (January 27th-February 2nd, 2025).”
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
Authors: Michail Ignatiadis, et al.
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.
Authors: Akshara Singareeka Raghavendra, et al.
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
Authors: Fabio Conforti, et al.
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
Authors: Janet A Dunn, et al.
Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers.
Authors: Madeline Gough, et al.
Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer.
Authors: Rupali Sood, et al.
A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer.
Authors։ Veronica Rendo, et al.
CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.
Authors: Qiangfeng Shi, et al.
Trends in Atypical Ductal Hyperplasia Diagnosis and Upgrade: A 20-Year Experience and Impact of MRI Use on Upgrade Rates.
Authors: Shruti Zaveri, et al.
Biological correlates associated with high-risk breast cancer patients identified using a computational method.
Authors: Jung Hun Oh, et al.
Ongoing Symptoms and Concerns Experienced by Low- Risk Breast Cancer Survivors Following Active Treatment.
Authors: Jessica R Schumacher, et al.
Understanding metastasis mixed-treatment responses through genomic analyses.
Authors: Susana Garcia-Recio, et al.
Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer.
Authors: Seunghyun Lee, et al.
Tumor cells upregulate neurotransmitter GABA in the choroid plexus through STAT6-Bestrophin1 signaling, promoting leptomeningeal dissemination.
Authors: Diganta Das, et al.
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib.
Authors: Sylvain Ladoire, et al.
Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the Surveillance, Epidemiology, and End Results database, 2010-2019.
Authors: Adrienne G Waks, et al.
Impact of a Nurse Navigator Program on Referral Rates and Use of Fertility Preservation Among Female Cancer Patients: A 14-Year Retrospective Cohort Study.
Authors: Mackenzie Naert, et al.
Unusual FDG PET Appearances in a Patient With Metastatic Breast Carcinoma.
Authors: Raima Kaleemi, et al.
Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression.
Authors: Jordan Baeker Bispo J, et al.
An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system.
Authors: Leah M Marcotte , et al.
Copy number amplification of FLAD1 promotes the progression of triple-negative breast cancer through lipid metabolism.
Authors: Xiao-Qing Song, et al.
